Search results
Author(s):
Stephen J Greene
Added:
10 months ago
ESC-HFA 23 — Dr Stephen Greene (Duke University School of Medicine, US) outlines the findings from the QoL study of the TRANSFORM-HF Trial (NCT03296813).
The TRANSFORM-HF trial is a randomized trial which compared torsemide to furosemide as a treatment for patients with heart failure. Around 2859 patients with heart failure were enrolled in the trial, whose clinical outcomes were measured across…
View more
Author(s):
David Pham
,
Justin L Grodin
Added:
3 years ago
Introduction
Advances in heart failure medical therapy over the past few decades have improved the prognosis of patients with this condition. Despite this, heart failure remains a significant burden to the medical system as the incidence of heart failure hospitalisation continues to rise.1 Diuretics have been a mainstay of therapy in heart failure to relieve congestion and improve symptoms…
View more
Author(s):
Ingibjörg Kristjánsdóttir
,
Tonje Thorvaldsen
,
Lars H Lund
Added:
3 years ago
From Acute Heart Failure Towards Worsening or De Novo Heart Failure
The natural history of heart failure (HF) is characterised by disease progression and episodes of worsening HF and acute decompensation requiring outpatient treatment intensification, emergency department or in-hospital care.
Acute HF (AHF), also known as acute decompensated HF, is defined as a progressive and sometimes rapid…
View more
Author(s):
Harriette Van Spall
,
Robert Mentz
Added:
1 year ago
AHA 22 - Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) sits down with PI, Dr Robert J Mentz (Duke University of Medicine, US) to discuss the findings of the TRANSFORM-HF trial (NCT03296813).
This study aimed to compare the loop diuretics furosemide and torsemide in the treatment of patients with heart failure.Over 2800 patients were enrolled in the trial and were randomized…
View more
Author(s):
Pierpaolo Pellicori
,
Kuldeep Kaur
,
Andrew L Clark
Added:
3 years ago
Heart failure (HF) is one of the most common reasons for admission to hospital. It is associated with long in-patient stays, and has a high in-hospital and post-discharge morbidity and mortality, whether left ventricular ejection fraction (LVEF) is reduced (HFREF) or normal (HeFNEF).1,2 Congestion, or fluid overload, is a classic clinical feature of patients presenting with HF. In some patients,…
View more
Author(s):
John GF Cleland
Added:
10 months ago
ESC-HFA 2023 – Prof John Cleland (University of Glasgow, Glasgow, UK) discusses the findings from a study that looked at the diagnostic of heart failure in a cohort of 1.1 million people using the NHS EMR database.
Finding presented at Heart Failure 2023, showed that more people treated with LD than receive diagnosis of heart failure, this disparity was greater in women compared to men.
…
View more
Author(s):
Jozine ter Maaten
Added:
7 months ago
ESC 2023 — Dr Jozine Ter Maaten (University Medical Centre Groningen, NL) joins us to outline the findings from the PUSH-AHF Study (NCT04606927).
PUSH-AHF (University Medical Center Groningen) aimed to assess the effect of natriuresis-guided therapy in patients with acute heart failure to improve diagnostic response, decongestion and clinical outcomes. 310 patients with a primary diagnosis of…
View more
Author(s):
Rafael de la Espriella
,
Gonzalo Núñez-Marín
,
Pau Codina
,
et al
Added:
5 months ago
Author(s):
Mauro Gori
,
James L Januzzi
,
Emilia D’Elia
,
et al
Added:
2 years ago
Author(s):
Harriette Van Spall
,
Adriaan A Voors
Added:
2 years ago
In this in-depth conversational interview, Late-breaker host Dr Harriette Van Spall (McMaster University, CA) meets PI, Prof Adriaan Voors (University Medical Center Groningen, NL) to discuss the EMPULSE trial. The aim of the trial was to evaluate empagliflozin compared with placebo among patients with acute decompensated heart failure.
Presented first at AHA 2021, the trial showed that that…
View more